![mobile-tech](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/09/mobile-tech.png)
License the latest technology from Imperial College London
Technology available for licensing
Imperial College London is among the world’s leading research universities, and one of the few focused exclusively on Science, Technology, Engineering, Medicine and Business. Technology developed by Imperial’s world-leading researchers is protected and packaged by our expert commercialisation specialists.
Available technologies span all areas of research undertaken at Imperial. If your business is considering licensing technology, you can view available technologies and enquire directly through this site.
Available technologies
Browse technologies and innovations derived from research undertaken by academics at Imperial College London
Artificial Intelligence (AI) tool for measuring eczema severity in diverse skin tones
An AI tool for remote assessment of eczema severity for diverse skin types.
PROPHSY: Proteome in Pulmonary Hypertension Assay Score
A model score calculated from levels of circulating plasma proteins for the diagnosis, prognosis, and treatment optimisation of Pulmonary Arterial Hypertension.
miRNA Signatures for Pulmonary Hypertension
miRNA biomarkers to identify patients with pulmonary hypertension (PH), and sub-classify patients with pulmonary arterial hypertension (PAH) and chronic thromembolic PH (CTEPH)
Long-lasting nanoparticles for controlled release drug delivery
A nanoparticle drug platform that can deliver small molecule drugs over a sustained period in a stable, low-toxic manner.
Ultrasound transducers and reconstruction methods for volumetric imaging
Innovative transducer designs and image reconstruction algorithms, enabling effective 3D/4D imaging in clinical practice
Novel inhibitors of NorA efflux pump for combating antimicrobial resistance
These novel compounds could be used in the treatment of antibiotic resistant bacterial infections and demonstrate that inhibitors of NorA efflux can prevent the emergence of further resistant strains.
Upcycling plastic waste into high-capacity sodium-battery anodes
Plastic waste upcycling into high-performance battery anodes for the next-generation of fast-charging and low-cost sodium-ion batteries (NIBs).
Filter system for the removal of haemolytic products from blood
A filter matrix for use in the removal of haemoglobin, haem and free iron from the blood to combat poor patient outcomes resulting from haemolysis.
Genetic constructs for localised population suppression of pest species
Efficient and localised suppression of wild pest populations
Invariant Natural Killer T cell (iNKT cell) engagers
An immunotherapy platform capable of enhancing the anti-tumour efficacy of invariant natural killer T cells (iNKT).
Featured inventor
Professor Marina Botto
Academic title - Head of Department, Director of Bioservices
Faculty - Faculty of Medicine, Department of Immunology and Inflammation
Upcoming Events
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Latest News
![Accelerated development of a potential treatment for cystic fibrosis](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/10/newseventsimage_1634653774994_mainnews2012_x4-400x284.jpg)
Accelerated development of a potential treatment for cystic fibrosis
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
![Natural Killer – licensing a cell therapy](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/09/karadimitris1-mobile--400x284.webp)
Natural Killer – licensing a cell therapy
Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more
![Imperial partner Apollo receives £100m to boost medical research at leading unis](https://cdn.statically.io/img/imperial.tech/wp-content/uploads/2021/10/newseventsimage_1623958345088_mainnews2012_x1-400x284.jpg)
Imperial partner Apollo receives £100m to boost medical research at leading unis
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.